Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bruce Booth sold 467,878 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the sale, the director owned 472,267 shares of the company’s […]

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Jason Rhodes sold 147,760 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $21.13, for a total transaction of $3,122,168.80. Following the sale, the director directly owned 1,106,036 shares of the company’s stock, valued […]

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Jason Rhodes sold 24,100 shares of Dyne Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $21.10, for a total transaction of $508,510.00. Following the sale, the director directly owned 1,081,044 shares in the company, valued at […]

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bruce Booth sold 134,720 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $100.51, for a total transaction of $13,540,707.20. Following the transaction, the director directly owned 597,047 shares in the company, valued at $60,009,193.97. […]

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the transaction, the director owned 6,200 shares in the company, […]

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) Director Jean Jacques Bienaime bought 1,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was acquired at an average cost of $10.19 per share, for a total transaction of $10,190.00. Following the purchase, the director owned 17,592 shares in the company, […]